Mechanism of HPV E6 proteins in cellular transformation

Seminars in Cancer Biology

Volumn 7, Issue 6, 1996, Pages 317-326

  Huibregtse, Jon M ^a   Beaudenon, Sylvie L ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Cervical cancer; E6 proteins; E6 AP; HPV; p53; Ubiquitin protein ligase

Indexed keywords

ONCOPROTEIN; PROTEIN P53; UBIQUITIN PROTEIN LIGASE; VIRUS PROTEIN;

HUMAN; NONHUMAN; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS CELL TRANSFORMATION; WART VIRUS;

EID: 0030391262     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1996.0041     Document Type: Review

References (85)

1. 1. DeVilliers EM (1989) Heterogeneity of the human papillomavirus group. J Virol 63:4898-4903
2. 2. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT (1989) HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8:3905-3910
3. 3. Münger K, Phelps WC, Bubb V, Howley PM, Schlegel R (1989) The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63:4417-4421
4. 4. Whyte P, Buchkovich KJ, Horowitz JM, Friend SH, Raybuck M, Weinberg RA, Harlow E (1988) Association between an oncogene and an antioncogene: the adenovirus E1a proteins bind to the retinoblastoma gene product. Nature 334:124-129
5. 5. Dyson N, Guida P, Münger K, Harlow E (1992) Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J Virol 66:6893-6902
6. 6. DeCaprio JA, Ludlow JW, Figge J, Shew J-Y, Huang C-M, Lee W-H, Marsilio E, Paucha E, Livingston DM (1988) SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54:275-283
7. 7. Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351:453-456
8. 8. Vogelstein B, Kinzler KW (1992) p53 Function and dysfunction. Cell 70:523-526
9. 9. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B (1992) Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830
10. 10. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW (1992) A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12:2866-2871
11. 11. Pietenpol JA, Tokino T, Thiagalingam S, El-Deiry WS, Kinzler KW, Vogelstein B (1994) Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 91:1998-2002
12. 12. Maltzman W, Czyzyk L (1984) UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4:1689-1694
13. 13. Kastan MB, Onyerkwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 53:6304-6311
14. 14. Lane DP (1992) p53, guardian of the genome. Nature 358:15-16
15. 15. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825
16. 16. Juven T, Barak Y, Zauberman A, George DL, Oren M (1993) Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8:3411-3416
17. 17. Han J, Sabbatini P, Perez D, Rao L, Modha D, White E (1996) The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev 10:461-477
18. 18. Ko LJ, Prives C (1996) p53: puzzle and paradigm. Genes Dev 10:1054-1072
19. 19. Friend S (1994) p53: A glimpse at the puppet behind the shadow play. Science 265:334-335
20. 20. Linzer DIH, Levine AJ (1979) Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43-52
21. 21. Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261-263
22. 22. Scheffner M, Werness BA, Huibregtse JM, Levin AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136
23. 23. Mietz JA, Unger T, Huibregtse JM, Howley PM (1992) The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 11:5013-5020
24. 24. Hubbert NL, Sedman SA, Schiller JT (1992) Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol 66:6237-6241
25. 25. Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L, Cho KR (1993) Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 90:3988-3992
26. 26. Band V, DeCaprio JA, Delmolino L, Kulesa V, Sager R (1991) Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells. J Virol 65:6671-6676
27. 27. Band V, Zajchowski D, Kulesa V, Sager R (1990) Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc Natl Acad Sci USA 87:463-467
28. 28. Scheffner M, Münger K, Byrne JC, Howley PM (1991) The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 88:5523-5527
29. 29. Butz K, Shahabeddin L, Geisen C, Spitkovsky D, Ullman A, Hoppe-Seyler F (1995) Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene 10:927-936
30. 30. Crook T, Wrede D, Vousen KH (1991) p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 6:873-875
31. 31. Paquette RL, Lee YY, Wilczynski SP, Karmakar A, Kizaki M, Miller CW, Koeffler HP (1993) Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer 72:1272-1280
32. 32. Ikenberg H, Matthay K, Schmitt B, Bauknecht T, Kiechle-Schwarx M, Goppinger A, Pfleiderer A (1995) p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas. Cancer 76:57-66
33. 33. Crook T, Vousden KH (1992) Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J 11:3935-3940
34. 34. Chowdary DR, Dermody JJ, Jha KK, Ozer HL (1994) Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol 14:1997-2003
35. 35. Gronostajski RM, Goldberg AL, Pardee AB (1984) Energy requirement for degradation of tumor associated protein p53. Mol Cell Biol 4:442-448
36. 36. Maki CG, Huibregtse JM, Howley PM (1996) In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res 56:2649-2654
37. 37. Ciechanover A, DiGiuseppe JA, Bercovich B, Orlan A, Richter JD, Schwartz AL, Brodeur GM (1991) Degradation of nuclear oncoproteins by the ubiquitin proteolysis system in vitro. Proc Natl Acad Sci USA 88:139-143
38. 38. Ciechanover A, Shkedy D, Oren M, Bercovich B (1994) Degradation of the tumor suppressor protein p53 by the ubiquitin-mediated proteolytic system requires a novel species of ubiquitin-carrier protein, E2. J Biol Chem 269:9582-9589
39. 39. Lowe SW, Ruley HE (1993) Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 7:535-545
40. 40. Debbas M, White E (1993) Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev 7:546-554
41. 41. Demers GW, Foster SA, Halbert CL, Galloway DA (1994) Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci USA 91:4382-4386
42. 42. White E (1994) p53, guardian of Rb. Nature 371:21-22
43. 43. Barbosa MS, Lowy DR, Schiller JT (1989) Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J Virol 63:1404-1407
44. 44. Chan S-Y, Delius H, Halpern AL, Bernard H-U (1995) Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. J. Virol 69:3074-3083
45. 45. Werness BA, Levine AJ, Howley PM (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79
46. 46. Huibregtse JM, Scheffner M, Howley PM (1991) A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 10:4129-4135
47. 47. Huibregtse JM, Scheffner M, Howley PM (1993) Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 13:775-784
48. 48. Huibregtse JM, Scheffner M, Beaudenon S, Howley PM (1995) A family of proteins structurally and function ally related to the E6-AP ubiquitin-protein ligase. Proc Natl Acad Sci USA 92:2563-2567
49. 49. Yamamoto Y, Huibregtse JM, Howley PM (1997) The human E6-AP gene (UBE3A) encodes three potential protein isoforms generated by differential splicing. Genomics, 41: 263-266
50. 50. Huibregtse JM, Scheffner M, Howley PM (1993) Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol 13:4918-4927
51. 51. Matsuura T, Sutcliffe JS, Fang P, Galjaard R-J, Jiang Y-H, Benton CS, Rommens JM, Beaudet AL (1997) De novo truncating mutations in the E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nature Genetics 15:74-77
52. 52. Kishino T, Lalande M, Wagstaff J (1997) UBE3A/ E6-AP mutations cause Angelman syndrome. Nature Genet 15:70-73
53. 53. Crook T, Tidy JA, Vousden KH (1991) Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67:547-556
54. 54. Foster SA, Demers GW, Etschei BG, Galloway DA (1994) The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol 68:5698-5705
55. 55. Li X, Coffino P (1996) High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol 70:509-516
56. 56. Schaffner M, Takahashi T, Huibregtse JM, Minna JD, Howley PM (1992) Interaction of the human papillomavirus type 16 oncoprotein with wild-type and mutant p53 proteins. J Virol 66:5100-5105
57. 57. Medcalf EA, Milner J (1993) Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation. Oncogene 8:2847-2851
58. 58. Molinari M, Milner J (1995) p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 E6. Oncogene 10:1849-1854
59. 59. Lechner MS, Laimins LA (1994) Inhibition of p53 DNA binding by human pappilomavirus E6 proteins. J Virol 68:4262-4278
60. 60. Martson NJ, Crook T, Vousden KH (1994) Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene 9:2707-2716
61. 61. Crook T, Ludwig RL, Marston NJ, Willkomm D, Vousden KH (1996) Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6. Virol 217:285-292
62. 62. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505
63. 63. Scheffner M, Huibregtse JM, Howley PM (1994) Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc Natl Acad Sci USA 91:8797-8801
64. 64. Scheffner M, Nuber U, Huibregtse JM (1995) Protein ubiquitination involving an E1-E2-E3 enzyme thioester cascade. Nature 373:81-83
65. 65. Nefsky B, Beach D (1996) Pub1 acts as an E6-AP-like protein ubiquitin ligase in the degradation of cdc25. EMBO J 15:1301-1312
66. 66. Jensen JP, Bates PW, Yang M, Vierstra RD, Weissman AM (1995) Identification of a family of closely related human ubiquitin conjugating enzymes. J Biol Chem 270:30408-30413
67. 67. Nuber U, Schwarz S, Kaiser P, Schneider R, Scheffner M (1996) Cloning of human ubiquitin-conjugating enzymes UbcH6 and UbcH7 (E2-F1) and characterization of their interaction with E6-AP and RSP5. J Biol Chem 271:2795-2800
68. 68. Girod PA, Vierstra RD (1993) A major ubiquitin conjugation system in wheat germ extracts involves a 15-kDa ubiquitin-conjugating enzyme (E2) homologous to the yeast UBC4/ UBC5 gene products. J Biol Chem 268:955-960
69. 69. Girod P-A, Carpenter TP, van Nocker S, Sullivan ML, Vierstra RD (1993) Homologs of the essential ubiquitin conjugating enzymes UBC1, 4 and 5 in yeast are encoded by a multigene family in Arabidopsis thaliana. Plant J 3:545-552
70. 70. Seufert W, Jentsch S (1990) Ubiquitin conjugating enzymes UBC4 and UBC5 mediate selective degradation of short-lived and abnormal proteins. EMBO J 9:543-550
71. 71. Chen P, Johnson P, Sommer T, Jentsch S, Hochstrasser M (1993) Multiple ubiquitin-conjugating enzymes participate in the in vivo degradation of the yeast MATa2 represser. Cell 74:357-389
72. 72. Rosa JL, Casaroli-Marano RP, Buckler AJ, Vilaro S, Barbacid M (1996) p619, a giant protein relate to the chromosome condensation regulator RCC1, stimulates guanine nucleotide exchange on ARF1 and Rab proteins. EMBO J 15:4262-4273
73. 73. Klingelhutz AJ, Foster SA, McDougall JK (1996) Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380:79-82
74. 74. von Knebel-Doeberitz M, Bauknecht T, Bartsch D, zur Hausen H (1991) Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells. Proc Natl Acad Sci USA 88:1411-1415
75. 75. von Knebel Doeberitz M, Rittmüller C, zur Hausen H, Dürst M (1992) Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPC E6-E7 anti-sense RNA. Int J Cancer 51:831-834
76. 76. Spitkovsky D, Aengeneyndt F, Braspenning J, von Knebel Doeberitz M (1996) p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene. Oncogene 13:1027-1035
77. 77. Band V, Dalal S, Delmolino L, Androphy EJ (1993) Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells. EMBO J 12:1847-1852
78. 78. Desaintes C, Hallez S, van Alphen P, Burny A (1992) Transcriptional activation of several heterologous promoters by the E6 protein of the human papillomavirus type 16. J Virol 66:325-333
79. 79. Lamberti C, Morrissey LC, Grossman SR, Androphy EJ (1990) Transcriptional transactivation by the human papillomavirus E6 zinc finger oncoprotein. EMBO J 9:1907-1913
80. 80. Sedman SA, Hubbert NL, Vas WC, Lowy DR, Schiller JT (1992) Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated trans-activation or transforming activity. J Virol 66:4201-4208
81. 81. Chen JC, Reid CE, Band V, Androphy EJ (1995) Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science 269:529-531
82. 82. Iftner T, Bierfelder S, Csapo Z, Phister H (1988) Involvement of human papillomavirus type 8 genes E6 and E7 in transformation and replication. J Virol 62:3655-3661
83. 83. Kiyono T, Hiraiwa A, Ishibashi M (1992) Differences in transforming activity and coded amino acid sequence among E6 gene of several papillomaviruses associated with epidermodysplasia verruciformis. Virology 186:628-639
84. 84. Steger G, Pfister H (1992) In vitro expressed HPV 8 E6 protein does not bind p53. Arch Virol 125:355-360
85. 85. Kiyono T, Hiraiwa AIS, Takahashi T, Ishibashi M (1994) Inhibition of p53-mediated transactivation of E6 of type 1, but not type 5, 8, or 47, human papillomavirus of cutaneous origin. J Virol 68:4656-4661